Johnson & Johnson (JNJ)

Investors were in growth mode in the last two years as the stock market delivered blockbuster returns.

While J&J is yet to give up on aticaprant, it decides to stop developing the drug for major depressive disorder due to a lack of sufficient efficacy.

While the market throws its tariff tantrum, several long-established companies with years of operational success have seen their shares move higher, displaying relative strength.

Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator. In this article...

Uncertainty socked the U.S. stock market in February, short-circuiting an early-year rally and saddling fund investors with losses. The post Stock Market Drama Highlights Trump's Game Of Chicken With ...

Johnson & Johnson said on Thursday it will discontinue a late-stage study of its add-on treatment for major depressive disorder due to insufficient efficacy in the target patient population.

The trade war is causing market volatility, with stocks falling and bonds performing well as investors seek hedges against economic slowdown fears. Dividend aristocrats, particularly low-volatility, d...

For nearly 129 years, the iconic Dow Jones Industrial Average (^DJI 1.14%) has served as a key barometer of Wall Street's health and stability. This index, which began its existence with a dozen mostl...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 15th to review first-quarter results. Joaqui...